Browse diseases

…Introduction Despite the availability of curative treatments, hepatitis C diagnosis and treatment coverage is suboptimal globally with fe…

…F/VEL) and sofosbuvir/daclatasvir (SOF/DCV) in the treatment of hepatitis C virus (HCV) infection. No study has evaluated the effect of GLE…

…5%) lost to follow up. 3 (1.4%) patients in Group 1 developed a hepatocellular carcinoma (HCC). Of the 46 patients in Group 2, 21 (46%) had a repeat LSM…

…2023, allowing comparison of longterm patterns.Results In 2023, Hepatitis C incidence ranged from 0.03 million cases (95% UI: 0.02–0.03) in…

…tudies and case series raised concerns about decreased rates of de novo HCC following DAA therapy, particularly in patients with advanced c…

…ue to the long-term complications including liver cirrhosis and hepatocellular carcinoma. Accordingly, it is imperative to evaluate the temporal trends …

…t-acting antivirals (DAAs) on hepatitis C control, acute/recent hepatitis C virus (HCV) infections continue to be diagnosed in contemporary…

…eaching rural health clinic to close five preventive care gaps: lung cancer screening, colon cancer screening, Shingrix vaccination, osteop…

… died of decompensated liver disease. 4 patients presented with hepatocellular carcinoma (HCC); all have subsequently died. In addition, 38 patients hav…

…is C elimination program to accelerate progress towards the WHO hepatitis C elimination target of 2030. This study assesses patient charact…

…public health concern in the general population globally. Viral hepatitis, a key driver of liver impairment, remains endemic in many coun…

…d as asymptomatic contacts of Neisseria gonorrhoeae (NG) and/or Chlamydia trachomatis (CT). Our goal was to shed light on current discrepancies betwe…